JWH-338
JWH-338 is a synthetic cannabinoid from the naphthoylindole family, which acts as a potent agonist of the cannabinoid receptors. It was developed by John W. Huffman and his team at Clemson University as part of research into the structure-activity relationships of cannabinoids.
Chemical Structure and Properties[edit | edit source]
JWH-338 is chemically classified as a naphthoylindole, which is a subclass of synthetic cannabinoids. The compound's structure includes a 1H-indole core with a 1,1-difluoropentyl chain at the 4-position and a naphthalen-1-yl group attached via a urea linkage. This specific configuration contributes to its high affinity for cannabinoid receptors.
Pharmacology[edit | edit source]
JWH-338 acts as a full agonist at both the CB1 and CB2 cannabinoid receptors. These receptors are part of the endocannabinoid system, which plays a role in regulating various physiological processes including pain sensation, mood, and appetite. The binding affinity of JWH-338 to these receptors is significant, making it a potent compound in terms of its psychoactive effects.
Legal Status[edit | edit source]
Due to its potent effects and potential for abuse, JWH-338, like many synthetic cannabinoids, has been subject to legal restrictions in various countries. It is often included in legislation that targets synthetic cannabinoids as a class, rather than being specifically named.
Research and Applications[edit | edit source]
JWH-338, along with other synthetic cannabinoids, has been used in scientific research to better understand the endocannabinoid system and the effects of cannabinoids on the human body. However, due to its potential for abuse and lack of therapeutic approval, its use is generally restricted to controlled laboratory settings.
Safety and Toxicity[edit | edit source]
The safety profile of JWH-338 is not well-documented, as is the case with many synthetic cannabinoids. However, compounds in this class have been associated with adverse effects such as tachycardia, hypertension, hallucinations, and psychosis. The lack of clinical data makes it difficult to fully assess the risks associated with its use.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
